These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3649341)

  • 21. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives.
    Hilfenhaus J; Niedrig M; Nowak T
    Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Viral safety of solvent-detergent treated blood products.
    Horowitz B; Prince AM; Horowitz MS; Watklevicz C
    Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory control of blood products in Canada.
    Boucher DW; Furesz J
    Dev Biol Stand; 1987; 67():221-8. PubMed ID: 3609478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration.
    Nowak T; Popp B; Gröner A; Schäfer W; Kalina U; Enssle K; Roth NJ
    Transfusion; 2017 May; 57(5):1184-1191. PubMed ID: 28191640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inactivation of lipid-enveloped viruses in labile blood derivatives by unsaturated fatty acids.
    Horowitz B; Piët MP; Prince AM; Edwards CA; Lippin A; Walakovits LA
    Vox Sang; 1988; 54(1):14-20. PubMed ID: 2831669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Industrial pasteurization of plasma and criteria of quality].
    Burnouf-Radosevich M; Burnouf T; Huart JJ
    Rev Fr Transfus Hemobiol; 1993 Jan; 36(1):93-102. PubMed ID: 8476493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses.
    Hilfenhaus J; Gröner A; Nowak T; Weimer T
    Transfusion; 1997 Sep; 37(9):935-40. PubMed ID: 9308641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations.
    Yunoki M; Urayama T; Tsujikawa M; Sasaki Y; Abe S; Takechi K; Ikuta K
    Br J Haematol; 2005 Feb; 128(3):401-4. PubMed ID: 15667545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation.
    Nowak T; Niedrig M; Bernhardt D; Hilfenhaus J
    Dev Biol Stand; 1993; 81():169-76. PubMed ID: 8174799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products.
    Reid KG; Cuthbertson B; Jones AD; McIntosh RV
    Vox Sang; 1988; 55(2):75-80. PubMed ID: 3142151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance of porcine circovirus and chicken anemia virus to virus inactivation procedures used for blood products.
    Welch J; Bienek C; Gomperts E; Simmonds P
    Transfusion; 2006 Nov; 46(11):1951-8. PubMed ID: 17076851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Properties and virus safety of a pasteurized antithrombin III concentrate].
    Karges HE; Fuhge P; Heimburger N
    Arzneimittelforschung; 1987 Jul; 37(7):756-8. PubMed ID: 2823838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific inactivation of viruses which can potentially contaminate blood products.
    Horowitz B
    Dev Biol Stand; 1991; 75():43-52. PubMed ID: 1794631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virus validation of plasma-derived products produced by Pharmacia, with particular reference to immunoglobulins.
    Eriksson B; Westman L; Jernberg M
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 3():S37-44. PubMed ID: 7749047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inactivation of Zika virus by solvent/detergent treatment of human plasma and other plasma-derived products and pasteurization of human serum albumin.
    Kühnel D; Müller S; Pichotta A; Radomski KU; Volk A; Schmidt T
    Transfusion; 2017 Mar; 57(3pt2):802-810. PubMed ID: 28019034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma derivatives and viral hepatitis.
    Gerety RJ; Aronson DL
    Transfusion; 1982; 22(5):347-51. PubMed ID: 6812245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
    Roberts PL; Dunkerley C; McAuley A; Winkelman L
    Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parvovirus B19 DNA in plasma pools and plasma derivatives.
    Schmidt I; Blümel J; Seitz H; Willkommen H; Löwer J
    Vox Sang; 2001 Nov; 81(4):228-35. PubMed ID: 11903998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.
    Kempf C; Stucki M; Boschetti N
    Biologicals; 2007 Mar; 35(1):35-42. PubMed ID: 16581263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.